$RGPX
REGENEREX PHARMA, INC. Stock $rgpx

$rgpx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000147237523000090 Filed on June 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2023
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$160.2K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$831.00		$3.420K
YoY Change	-22.41%		-3.09%
% of Gross Profit
Operating Expenses	$160.2K		$96.17K
YoY Change	826.66%		-23.84%
Operating Profit	-$160.2K		-$96.17K
YoY Change	826.66%		-23.84%
Interest Expense	$18.51K		$66.79K
YoY Change	19.26%		13.08%
% of Operating Profit
Other Income/Expense, Net	-$25.40K		-$41.16K
YoY Change	329.14%		-35.5%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$185.6K		-$137.3K
YoY Change	699.75%		-29.79%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding	277.1M shares	277.1M shares	277.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$67.75K	$1.135K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$23.30K
Receivables
Other Receivables
Total Short-Term Assets	$91.05K	$1.135K
YoY Change	2082.5%	-85.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$948.6K	$5.404K
YoY Change	14826.04%	-27.23%
TOTAL ASSETS
Total Short-Term Assets	$91.05K	$1.135K
Total Long-Term Assets	$948.6K	$5.404K
Total Assets	$1.040M	$6.539K
YoY Change	9775.6%	-57.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$96.50K	$75.15K
YoY Change	67.86%	19.23%
Accrued Expenses	$76.97K	$125.8K
YoY Change	-13.35%	37.22%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$801.7K	$776.8K
YoY Change	7.34%	17.61%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$801.7K	$776.8K
Total Long-Term Liabilities		$0.00
Total Liabilities	$2.124M	$1.129M
YoY Change	108.33%	12.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.258M	-$2.072M
YoY Change	15.31%	7.1%
Common Stock	$277.3K	$277.1K
YoY Change	0.08%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.084M	-$1.123M
YoY Change
Total Liabilities & Shareholders Equity	$1.040M	$6.539K
YoY Change	9775.6%	-57.32%

Cashflow Statement

Concept	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$185.6K	-$137.3K
YoY Change	699.75%	-29.79%
Depreciation, Depletion And Amortization	$831.00	$3.420K
YoY Change	-22.41%	-3.09%
Cash From Operating Activities	-$121.2K	-$76.16K
YoY Change	245.72%	8.93%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$3.629K	-$1.398K
YoY Change		-83.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$191.5K	$76.06K
YoY Change	461.54%	2.42%
NET CHANGE
Cash From Operating Activities	-$121.2K	-$76.16K
Cash From Investing Activities	-$3.629K	-$1.398K
Cash From Financing Activities	$191.5K	$76.06K
Net Change In Cash	$66.62K	-$1.505K
YoY Change	-6982.13%	-64.69%
FREE CASH FLOW
Cash From Operating Activities	-$121.2K	-$76.16K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Interest Paid InterestPaid		usd
CY2022	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment		usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001357878
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent		usd
CY2022Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross		usd
CY2022Q1	RGPX	Notes Payable Related Parties NotesPayableRelatedParties		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2023	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations		usd
CY2023	us-gaap	Payments For Software PaymentsForSoftware		usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	us-gaap	Interest Paid InterestPaid		usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1		usd
CY2022	RGPX	Common Stock Issued For Purchase Of Intellectual Property CommonStockIssuedForPurchaseOfIntellectualProperty		shares
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-53230
CY2023	dei	Entity Registrant Name EntityRegistrantName	REGENEREX PHARMA, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0479983
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	5348 Vegas Drive #177
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Las Vegas
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89108
CY2023	dei	City Area Code CityAreaCode	(702)
CY2023	dei	Local Phone Number LocalPhoneNumber	273-3772
CY2023	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par value per share
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Public Float EntityPublicFloat	0	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	277147660	shares
CY2023	dei	Auditor Firm AuditorFirmId	3501
CY2023	dei	Auditor Name AuditorName	dbbmckennon
CY2023	dei	Auditor Location AuditorLocation	Newport Beach, California
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1135	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2640	usd
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5256	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	1135	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	7896	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	26397	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23174	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4203	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7426	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	197	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	0	usd
CY2023Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1201	usd
CY2023Q1	us-gaap	Assets Assets	6539	usd
CY2022Q1	us-gaap	Assets Assets	15322	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	75145	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	63027	usd
CY2023Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	131887	usd
CY2022Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	131687	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	221192	usd
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	221192	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	125787	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	91667	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	222771	usd
CY2022Q1	us-gaap	Notes Payable Current NotesPayableCurrent	152880	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	776782	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	660453	usd
CY2023Q1	us-gaap	Notes Payable NotesPayable	314704	usd
CY2022Q1	us-gaap	Notes Payable NotesPayable	340486	usd
CY2023Q1	RGPX	Notes Payable Related Parties NotesPayableRelatedParties	38000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1129486	usd
CY2022Q1	us-gaap	Liabilities Liabilities	1000939	usd
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	675000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	675000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	277112660	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	277112660	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	277112660	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	277112660	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	277113	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	277113	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	671963	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	671963	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2072023	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1934693	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1122947	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-985617	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6539	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15322	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	96171	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	126267	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	96171	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	126267	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-96171	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-126267	usd
CY2023	us-gaap	Interest Expense InterestExpense	66788	usd
CY2022	us-gaap	Interest Expense InterestExpense	59063	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	25629	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4751	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-41159	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-63814	usd
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-137330	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-190081	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-5510	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-137330	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-195591	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.00
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.00
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	0.00
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	0.00
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	277112660	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	183414030	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-137330	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-195591	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-5510	usd
CY2023	us-gaap	Depreciation Depreciation	3420	usd
CY2022	us-gaap	Depreciation Depreciation	3529	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	25629	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4751	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	45000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5256	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-4043	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	78119	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	76432	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-76164	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-64412	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-5510	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-76164	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69922	usd
CY2022	us-gaap	Payments For Software PaymentsForSoftware	8600	usd
CY2023	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	1398	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1398	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8600	usd
CY2023	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	200	usd
CY2022	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	695	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	37857	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	73565	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	40500	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-2500	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	76057	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	74260	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1505	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4262	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2640	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6902	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1135	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2640	usd
CY2023	RGPX	Accrued Interest Converted Into Note Payable To Shareholder AccruedInterestConvertedIntoNotePayableToShareholder	30294	usd
CY2022	RGPX	Accrued Interest Converted Into Note Payable To Shareholder AccruedInterestConvertedIntoNotePayableToShareholder	42818	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	150000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-835026	usd
CY2022	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	45000	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-195591	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-985617	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-985617	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-137330	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1122947	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin: 0px; font-size: 10pt"> </p> <p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; font-size: 10pt"><b>NOTE 1 – NATURE OF OPERATIONS</b></p> <p style="margin-top: 0px; margin-bottom: 0px; font-size: 10pt"> </p> <p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: justify; font-size: 10pt">Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005. The Company’s business was to develop and market proprietary skincare products that were to be sold online. The majority of manufacturing, distribution, marketing, and sales operations were outsourced. The Company’s attempt over the past four years to build a business that marketed skincare products online has not come to fruition, so management decided to change the business focus and look for other opportunities.</p> <p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15<sup>th</sup> of the following month, for a period of 60 months. The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Management has decided to focus on this new business development. The financial results for periods prior to the abandonment of the previous business line have been reflected in the accompanying statement of operations as discontinued operations as this change represented a strategic shift in our business that had a major effect on our operations and financial results. There were no assets or liabilities related to this area as of March 31, 2023 or 2022.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Risks and Uncertainties</i></p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position and cash flows.</p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has a lack of revenue history and has had a limited history of operations with the new business focus. No revenue has historically been derived from the assets purchased. Regenerex can give no assurance of success or profitability to the Company’s investors.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Companies business is to develop and market Woundcare Healing products. The Company has three technologies for different types of wound conditions:</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse"> <tbody> <tr> <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt"> </p></td> <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt"><span style="text-align: justify; text-indent: -24px; float: none">●</span></p></td> <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt"><span style="text-decoration: underline">The first is for closing chronic wounds,</span></p></td> </tr> <tr> <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt"> </p></td> <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt"><span style="text-align: justify; text-indent: -24px; float: none">●</span></p></td> <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt"><span style="text-decoration: underline">the second is for accelerating closure of acute or surgical wounds, and</span></p></td> </tr> <tr> <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt"> </p></td> <td style="width: 0.5in; vertical-align: top"><p style="margin: 0px; font-size: 10pt"><span style="text-align: justify; text-indent: -24px; float: none">●</span></p></td> <td style="text-align: justify; vertical-align: top"><p style="margin: 0px; font-size: 10pt"><span style="text-decoration: underline">the third solves the issue on contamination of all types of wounds including the destruction of biofilms</span>.</p></td> </tr> </tbody> </table> <p style="text-align: justify; margin-top: 0px; margin-bottom: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The current product technology provides the Company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S. and global markets.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Currently, there are no products available on the market that are successful in healing chronic, non-healing wounds through the down regulation of proteases. Management believes that this will provide the Company with a distinct advantage over other companies providing services in this sector.</p> <p style="margin-top: 0pt; margin-bottom: 0pt"><span class="adv_highlightanchor adv_pagination" id="page_19"/></p> <p style="margin: 0; font-size: 10pt"> </p> <p style="margin: 0; font-size: 10pt"/> <p style="margin: 0px; text-align: justify; font-size: 10pt">The wound care healing space is well suited for Home Care service providers that are funded by the US Government. The majority of manufacturing and distribution will be outsourced. However, strategic planning and development will be performed internally by the Company.</p>
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2005-11-18
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	10000000	usd
CY2023Q1	RGPX	Current Liabilities In Excess Of Current Assets CurrentLiabilitiesInExcessOfCurrentAssets	775647	usd
CY2023Q1	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	38000	usd
CY2022Q1	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	0	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	1725	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Basis of Presentation and Use of Estimates</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">These financial statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could ultimately differ from those estimates.</p> <p style="margin-top: 0pt; margin-bottom: 0pt"><span class="adv_highlightanchor adv_pagination" id="page_20"/></p>
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P3Y
CY2023	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P3Y
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3223	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3529	usd
CY2023	us-gaap	Property Plant And Equipment Preproduction Design And Development Costs PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts	<p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Computer Equipment</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Expenditure related to the maintenance of the Company’s computer equipment is expensed as incurred. Purchases of computer equipment with costs over $500 are capitalized and depreciated over the computer’s estimated useful life of three (3) years. Depreciation expense for the years ended March 31, 2023 and 2022 was $197 and $0, respectively.</p>
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	212000	usd
CY2022Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	212000	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	9192	usd
CY2022Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	9192	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	221192	usd
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	221192	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	4800	usd
CY2022Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	12500	usd
CY2023Q1	RGPX	Accrued Administration Expenses AccruedAdministrationExpenses	9744	usd
CY2022Q1	RGPX	Accrued Administration Expenses AccruedAdministrationExpenses	4419	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	111243	usd
CY2022Q1	us-gaap	Interest Payable Current InterestPayableCurrent	74748	usd
CY2023Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	125787	usd
CY2022Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	91667	usd
CY2023	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.10	pure
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13171	usd
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13120	usd
CY2023Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	131887	usd
CY2022Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	131687	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	2500	usd
CY2021Q4	us-gaap	Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued	150000000	shares
CY2021Q4	us-gaap	Business Combination Contingent Consideration Arrangements Description BusinessCombinationContingentConsiderationArrangementsDescription	and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months.
CY2020	us-gaap	Debt Instrument Repurchase Date DebtInstrumentRepurchaseDate	2022-03-31
CY2024Q1	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	222771	usd
CY2025Q1	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	314704	usd
CY2023Q1	us-gaap	Accounts Payable Interest Bearing Current And Noncurrent AccountsPayableInterestBearingCurrentAndNoncurrent	51892	usd
CY2022Q1	us-gaap	Accounts Payable Interest Bearing Current And Noncurrent AccountsPayableInterestBearingCurrentAndNoncurrent	42677	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	675000000	shares
CY2023	RGPX	Shares Transferred SharesTransferred	45000000	shares
CY2023	RGPX	Shares Transferred Estimated Fair Value SharesTransferredEstimatedFairValue	45000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	45000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-4.8	pure
CY2023	RGPX	Effective Income Tax Rate Reconciliation Accounts Payable And Accrued Liabilities EffectiveIncomeTaxRateReconciliationAccountsPayableAndAccruedLiabilities	0.071	pure
CY2022	RGPX	Effective Income Tax Rate Reconciliation Accounts Payable And Accrued Liabilities EffectiveIncomeTaxRateReconciliationAccountsPayableAndAccruedLiabilities	0.038	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.068	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.005	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.213	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.195	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2023Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	14300	usd
CY2022Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	16700	usd
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	345800	usd
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	314200	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	360100	usd
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	330900	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	29200	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	38200	usd
CY2023Q1	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	1600000	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	10000000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1650	usd
CY2023Q2	us-gaap	Debt Instrument Issuance Date1 DebtInstrumentIssuanceDate1	2023-04-12

Files In Submission

Name	View Source	Status
0001472375-23-000090-index-headers.html	Edgar Link	pending
0001472375-23-000090-index.html	Edgar Link	pending
0001472375-23-000090.txt	Edgar Link	pending
0001472375-23-000090-xbrl.zip	Edgar Link	pending
exhibit31-1.htm	Edgar Link	pending
exhibit31-2.htm	Edgar Link	pending
exhibit32-1.htm	Edgar Link	pending
exhibit32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ixform10k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ixform10k_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regenerexlogo.gif	Edgar Link	pending
report.css	Edgar Link	pending
rgpx-20230331.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
rgpx-20230331_cal.xml	Edgar Link	unprocessable
rgpx-20230331_pre.xml	Edgar Link	unprocessable
rgpx-20230331_def.xml	Edgar Link	unprocessable
rgpx-20230331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGPX
REGENEREX PHARMA, INC. Stock $rgpx

2023 Q2 Form 10-K Financial Statement

#000147237523000090 Filed on June 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGPX REGENEREX PHARMA, INC. Stock $rgpx

2023 Q2 Form 10-K Financial Statement

#000147237523000090 Filed on June 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGPX
REGENEREX PHARMA, INC. Stock $rgpx